Market Trends– category –
-
Yole Group Forecasts Advanced Packaging Market to Double to Over $120 Billion by 2031, Driven by AI and HPC Demand
Yole Group (via advancedpackaging.news) France Overview Yole Group's latest report projects the global advanced packaging market to more than double from $55 billion in 2025 to over $120 billion by 2031, fueled by next-generation AI and ... -
TSMC Pledges Additional $100 Billion for Arizona Fabs, Total U.S. Investment Reaches $265 Billion to Boost Advanced Chip Manufacturing
Supply Chain Dive USA Overview TSMC has committed an additional $100 billion to its semiconductor manufacturing and packaging facilities in Arizona, elevating its total U.S. investment to $265 billion. This expansion includes four new ad... -
AI Chip Packaging Bottleneck Intensifies: NVIDIA Explores Intel EMIB Amid TSMC CoWoS Shortage, Amkor Commits $7B to Arizona
The Economy Japan Overview The burgeoning AI chip market faces a critical bottleneck in advanced packaging, particularly with TSMC's CoWoS technology, prompting NVIDIA to reportedly consider Intel's EMIB for future GPU production. This s... -
Samsung Biologics Acquires PolyPeptide in All-Cash Offer: Accelerating Multi-Modality Strategy and Global Network Expansion
PR Newswire South Korea Overview Samsung Biologics announced an all-cash offer to acquire PolyPeptide, accelerating its multi-modality strategy and expanding its global manufacturing network across the U.S., Europe, and India. This acqui... -
Oral GLP-1 Market Shift: Foundayo (orforglipron) Gains FDA Approval After Oral Wegovy, Demonstrating Dosing Convenience Advantage
GoodRx Health USA Overview The oral GLP-1 receptor agonist market sees a new entrant as Foundayo (orforglipron) received FDA approval on April 1, 2026, becoming the second oral GLP-1 therapy after oral Wegovy (semaglutide). Foundayo offe... -
Arrowhead’s Plozasiran Achieves Up to 81% Triglyceride Reduction in Severe Hypertriglyceridemia Phase 3, Pressuring Ionis
Fierce Biotech USA Overview Arrowhead Pharmaceuticals has reported robust Phase 3 SHASTA-3 and SHASTA-4 trial data for its siRNA therapeutic, plozasiran, in patients with severe hypertriglyceridemia (sHTG), putting pressure on competitor... -
Hongene Biotech: Scaling Oligonucleotide Manufacturing Crucial for Surging siRNA Demand in Cardiometabolic Diseases
Hongene Biotech China Overview Hongene Biotech emphasizes the critical need for a dramatic scale-up in oligonucleotide manufacturing to meet the surging demand for siRNA therapeutics targeting cardiometabolic diseases. Driven by the succ... -
DelveInsight Reports Over 80 Molecular Glue Drug Candidates in Clinical Pipeline, Highlighting Market Boom
GlobeNewswire USA Overview DelveInsight's comprehensive report reveals over 80 molecular glue drug candidates in clinical development, signifying rapid expansion in this novel therapeutic modality. Key advancements include Nested Therape... -
Stellantis Plans 2026 Demonstration Fleet of EVs Powered by Factorial Energy’s Solid-State Batteries
Benchmark Minerals Intelligence USA Overview Automotive giant Stellantis announced plans to deploy a demonstration fleet of electric vehicles (EVs) powered by Factorial Energy's all-solid-state batteries in 2026. Factorial Energy, a U.S.... -
China Defines the Future: First National Standard for Vehicle Solid-State Batteries ‘GB/T 43568-2026’ Eliminates Ambiguity
Not specified China Overview Effective July 1, 2026, China's 'GB/T 43568-2026' marks the world's inaugural national standard for vehicle solid-state batteries, decisively clarifying industry definitions. It mandates a liquid electrolyte ...
